美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

2倍做多NVO ETF-Defiance

18.63

-0.2200-1.17%

盤後：18.58-0.0500-0.27%19:48 EST

成交量：39.11萬

成交額：744.54萬

市值：5,250.12萬

市盈率：- -

高：19.64

開：19.29

低：18.52

收：18.85

52周最高：105.60

52周最低：14.59

股本：281.81萬

流通股本：279.81萬

量比：0.21

換手率：13.98%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

減肥藥戰局生變：「雙寡頭」分出高下，全球價格血戰中的國產謀突圍丨行業風向標

巔峯之戰！2026藥王爭霸：禮來封神，艾伯維、賽諾菲血拼，強生跌下神壇

諾和諾德減重藥廣告被指誤導消費者，FDA發出警告

藥王易主、山寨藥攪局、專利懸崖倒計時、被指虛假宣傳，諾和諾德全球防線告急

华夏时报网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NVOX"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":18.63,"timestamp":1770757200000,"preClose":18.85,"halted":0,"volume":391124,"hourTrading":{"tag":"盘后","latestPrice":18.58,"preClose":18.63,"latestTime":"19:48 EST","volume":8590,"amount":159548.7515,"timestamp":1770770891644,"change":-0.05,"changeRate":-0.002684,"amplitude":0.009125},"delay":0,"changeRate":-0.011671087533156627,"floatShares":2798101,"shares":2818101,"eps":0,"marketStatus":"未開盤","change":-0.22,"latestTime":"02-10 16:00:00 EST","open":19.29,"high":19.64,"low":18.52,"amount":7445402.045088,"amplitude":0.059416,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1770800400000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":18.85,"sharesOutstanding":2798101,"nav":18.82,"aum":52660260.82,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":19.34,"preClose":18.85,"latestTime":"09:29 EST","volume":11118,"amount":212792.51628,"timestamp":1770733781052,"change":0.49,"changeRate":0.025995,"amplitude":0.037666},"postHourTrading":{"tag":"盘后","latestPrice":18.58,"preClose":18.63,"latestTime":"19:48 EST","volume":8590,"amount":159548.7515,"timestamp":1770770891644,"change":-0.05,"changeRate":-0.002684,"amplitude":0.009125},"volumeRatio":0.211669,"impliedVol":0.8922,"impliedVolPercentile":0.592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":2798101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.211669,"shares":2818101,"dividePrice":0,"high":19.64,"amplitude":0.059416,"preClose":18.85,"low":18.52,"week52Low":14.5902,"pbRate":"--","week52High":105.6,"institutionHeld":0,"latestPrice":18.63,"eps":0,"divideRate":0,"volume":391124,"delay":0,"ttmEps":0,"open":19.29,"prevYearClose":21.89,"prevWeekClose":17.59,"prevMonthClose":28.89,"prevQuarterClose":21.89,"fiveDayClose":20.05,"twentyDayClose":29.9,"sixtyDayClose":22.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610198552","title":"減肥藥戰局生變：「雙寡頭」分出高下，全球價格血戰中的國產謀突圍丨行業風向標","url":"https://stock-news.laohu8.com/highlight/detail?id=2610198552","media":"钛媒体APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610198552?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 14:01","pubTimestamp":1770789670,"startTime":"0","endTime":"0","summary":"2月9日，诺和诺德宣布对远程医疗公司Hims提起专利侵权诉讼。礼来也公开支持FDA行动，谴责非法仿制药对患者健康的危害。在专利战爆发的同时，FDA对诺和诺德的双面监管则更具深意。FDA要求诺和诺德15个工作日内提交整改方案，否则将限制产品推广。中国市场成必争之地随着GLP-1减肥药的竞争进入深水区，价格战已从欧美市场蔓延至全球，而中国市场成为巨头角力的关键阵地，国产药企则在仿制药与创新药两条赛道上加速突围。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211141535a6ed962b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211141535a6ed962b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVOH","NVOX","BK4585","BK4007","NVO","BK4588","LLY","BK4532","LU1093756168.USD","LU1093756325.SGD","BK4599","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0154236417.USD"],"gpt_icon":0},{"id":"2610625648","title":"巔峯之戰！2026藥王爭霸：禮來封神，艾伯維、賽諾菲血拼，強生跌下神壇","url":"https://stock-news.laohu8.com/highlight/detail?id=2610625648","media":"E药经理人","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610625648?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 21:18","pubTimestamp":1770729506,"startTime":"0","endTime":"0","summary":"2026年畅销药战场，风云诡谲，格局重塑。回望战场，自2023年底减重适应证获批以来，礼来替尔泊肽仅用两年时间，便以翻倍之势，硬生生从诺和诺德手中夺走“药王”桂冠。强生乌司奴单抗在2025年销售额骤降41%，仅余60.78亿美元。2026年的全球自免药王或将在艾伯维和赛诺菲之中产生。前者手握利生奇珠单抗，2026年狂揽175.62亿美元，增速接近50%，锋芒毕露。此外，艾伯维还在探索体内CAR-T疗法，用于自免疾病治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210212833a493d0bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210212833a493d0bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765059.SGD","LU1267930813.SGD","LU0345769128.USD","IE00BKDWB100.SGD","LU0466842654.USD","BK4007","BK4550","LU0354030511.USD","SG9999014898.SGD","LU0795875169.SGD","IE00B7KXQ091.USD","LU0316494557.USD","LU2552382215.SGD","LU2468319806.SGD","LU1718418525.SGD","LU0353189680.USD","LU0225283273.USD","LU0882574139.USD","LU0158827948.USD","IE0004445015.USD","BK4516","LU1093756325.SGD","LU0820561818.USD","IE00BVYPNW00.USD","LU0124676726.USD","LU1032466523.USD","IE00BSNM7G36.USD","LU2237438978.USD","LU1988902786.USD","LU0079474960.USD","SG9999014906.USD","LU0345770308.USD","LU0094547139.USD","BK4504","LU0097036916.USD","LU2361045086.USD","LU1496350502.SGD","LU1261432733.SGD","LU1623119135.USD","LU2213496289.HKD","LU1712237335.SGD","SG9999018857.SGD","LU2324357040.USD","LU2129689514.USD","IE00B4JS1V06.HKD","LU0061475181.USD","LU0787776722.HKD","IE00B1XK9C88.USD","IE00BN8TJ469.HKD","LU2592432038.USD","IE00BZ1G4Q59.USD","LU1035775433.USD","LU2552382132.HKD","LU1244550221.USD","LU2750360641.GBP","LLYZ","LU2087625088.SGD","IE00BFTCPJ56.SGD","LU1064131342.USD","LU1066051811.HKD","IE00BN29S564.USD","LU1989771016.USD","LU0689472784.USD","LLY","LU1066051498.USD","SGXZ99366536.SGD","LU0320765992.SGD","LU0210536198.USD","LU1059921491.USD","LU2357305700.SGD","LU1032955483.USD","LU0964807845.USD","IE00BJJMRZ35.SGD","LU2236285917.USD","LU2108987350.USD","SG9999001176.SGD","LU0154236417.USD","LU2756315318.SGD","LU1267930730.SGD","LU0058720904.USD","SG9999015986.USD","LU1894683264.USD","NVO","IE00BFSS8Q28.SGD","LU1868837136.USD","LU1585245621.USD","LU1323610961.USD","LU1093756168.USD","LU0417517546.SGD","LU2347655156.SGD","LU1069344957.HKD","LU0323591593.USD","LU0820561909.HKD","LU0385154629.USD","IE000M9KFDE8.USD","LU0070217475.USD","IE00BGHQF631.EUR","LU1929549753.HKD","LU2746668461.USD","LU1430594728.SGD","LU1914381329.SGD","LU0432979614.USD","LU2133065610.SGD","LU1244550577.SGD","LU2089984988.USD","LU2491050071.SGD","LU2361044865.SGD","IE00BFXG1179.USD","LU0471298694.HKD","LU0320765646.SGD","LU1868836591.USD","LU1720051108.HKD","LU2552382058.USD","LU0109394709.USD","BK4533","IE00B19Z3581.USD","LU0345770993.USD","LU0203347892.USD","LU2430703095.HKD","BK4559","LU1814569148.SGD","BK4534","LU1506573853.SGD","LU2896262040.SGD","LU0820562030.AUD","LU2023250504.SGD","LU0823416689.USD","LU0683600562.USD","LU0345769631.USD","LU2360106947.USD","LU0203201768.USD","LU0354030438.USD","LU1732799900.SGD","LU2168563687.JPY","LU0889566641.SGD","LU1551013342.USD","IE00B1BXHZ80.USD","LU2168564222.USD","LU1244550494.USD","SG9999013999.USD","LU2237443549.SGD","NVOX","LU0823434740.USD","IE00BLSP4239.USD","IE0002270589.USD","LU1291159041.SGD","SGXZ81514606.USD","LU0912757837.SGD","SG9999015945.SGD","IE00B7SZLL34.SGD","SG9999002232.USD","LU2023250330.USD","IE00BDGV0183.EUR","IE00BJLML261.HKD","LU0889565916.HKD","LU1145028129.USD","LU2430703251.USD","BK4581","ABBV","LU1804176565.USD","SG9999015978.USD","LU0234570918.USD","LU2265009873.SGD","LU2417539215.USD","SGXZ57979304.SGD","LU1629891620.HKD","BK4585","IE00BK4W5L77.USD","BK4592","LU0456855351.SGD","LU2237443895.HKD","IE00BJJMRX11.SGD","IE00BJT1NW94.SGD","IE00BKVL7J92.USD","LU2430703178.SGD","LU2505996509.AUD","SG9999014880.SGD","BK4532","IE00B3T34201.USD","LU0109391861.USD","LU2491050154.USD","LU0792757196.USD","LU1983299246.USD","BK4568","IE0005OL40V9.USD","LU1023059063.AUD","LU0106261372.USD","LU1196500208.SGD","LU1232071149.USD","LU2237443622.USD","LU0256863811.USD","LU0985320562.USD","LU0203345920.USD","LLYX","IE0002141913.USD","IE00BKPKM429.USD","SNY","LU0256863902.USD","LU1057294990.SGD","LU2211815571.USD","LU1066051225.USD","LU1974910355.USD","IE00B42XCP33.USD","LU1061106388.HKD","IE00B19Z3B42.SGD","LU2471134952.CNY","LU0098860793.USD","SG9999001440.SGD","LU0672654240.SGD","BK4588","LU2746668974.SGD","SG9999001176.USD","LU1280957306.USD","LU2602419157.SGD","LU2112291526.USD","LU1778281490.HKD","LU1674673691.USD","LU1720051017.SGD","LU2237443465.HKD","LU2168564149.EUR","IE00B3PB1722.GBP","LU0289739699.SGD","GB00BDT5M118.USD","SG9999015952.SGD","LU1162221912.USD","SGXZ31699556.SGD","LU0122379950.USD","LU2271345857.HKD","IE00B775H168.HKD","SG9999018865.SGD","BK4599","LU0234572021.USD","LU2456880835.USD","LU2237443978.SGD","LU2089283258.USD","LU0471298777.SGD","LU2129689431.USD","LU2471134879.HKD","IE0009355771.USD","LU0943347566.SGD","LU2462157665.USD","LU2168564495.EUR","LU2461242641.AUD","SG9999017495.SGD","LU1548497426.USD","IE0004445239.USD","LU0238689110.USD","LU2471134523.USD","LU2361044949.HKD","LU2756315664.SGD","LU1868836757.USD","LU0198837287.USD","IE00BFSS7M15.SGD","LU1221951129.SGD","SGXZ51526630.SGD","LU1074936037.SGD","IE00BVYPNV92.GBP","LU2089284900.SGD","LU1366192091.USD","LU0158827781.USD","LU0266013472.USD","LU0823434583.USD","LU2106854487.HKD","LU1127390331.HKD","LU0203202063.USD","LU2129689605.HKD","LU1221951046.USD","LU0114720955.EUR","LU2168564065.EUR","LU2028103732.USD","IE00BBT3K403.USD","LU0006306889.USD","ELIL","LU1868837300.USD","IE00BK4W5M84.HKD","LU2505996681.GBP","IE00BJJMRY28.SGD","LU2063271972.USD","LU2237443382.USD","LU0795875086.SGD","LU1674673428.USD","IE00BLSP4452.SGD","LU2264538146.SGD","LU0882574055.USD","LU0640476718.USD","LU1935042991.SGD","LU2491049909.HKD","IE00B2B36J28.USD","LU1917777945.USD","SG9999014914.USD","IE00BWXC8680.SGD","IE0034235303.USD","LU2111349929.HKD","ELIS","LU0708995401.HKD","LU0096364046.USD","LU2750360997.AUD","SG9999002224.SGD","LU2023251221.USD","NVOH","IE00B4R5TH58.HKD","LU1551013425.SGD","LU1868836914.USD","LU1732800096.USD","LU2471134796.USD","LU0786609619.USD","LU1066053197.SGD","LU0353189763.USD","LU0689626769.HKD","LU1894683348.USD"],"gpt_icon":0},{"id":"2610612515","title":"諾和諾德減重藥廣告被指誤導消費者，FDA發出警告","url":"https://stock-news.laohu8.com/highlight/detail?id=2610612515","media":"第一财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610612515?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 16:12","pubTimestamp":1770711166,"startTime":"0","endTime":"0","summary":"但诺和诺德称，FDA的最新警告不涉及超级碗广告，而是常规播放的关于司美格鲁肽口服减重药电视广告。去年年底，司美格鲁肽口服减重药获得美国FDA批准，成为全球首个获批上市的GLP-1类口服减重药，早于竞争对手礼来。在FDA的警告信中，监管机构认为，诺和诺德的电视广告误导性地暗示，与其他GLP-1类减重药相比，司美股鲁肽口服减重药效果更佳。FDA要求诺和诺德立即采取行动解决这种违规行为，包括停止所有包含误导性信息的广告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021016173295408f1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021016173295408f1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVOH","IE00BKVL7J92.USD","BK4588","LU1093756325.SGD","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4599","NVO","BK4007","BK4585","BK4532","NVOX","LU1093756168.USD"],"gpt_icon":0},{"id":"2610961801","title":"藥王易主、山寨藥攪局、專利懸崖倒計時、被指虛假宣傳，諾和諾德全球防線告急","url":"https://stock-news.laohu8.com/highlight/detail?id=2610961801","media":"华夏时报网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610961801?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 14:06","pubTimestamp":1770703564,"startTime":"0","endTime":"0","summary":"作为全球糖尿病与肥胖症治疗领域的绝对巨头，诺和诺德曾凭借司美格鲁肽系列产品缔造医药行业的增长神话，市值一度登顶欧洲上市公司榜首。然而进入2026年，这家丹麦制药巨头却遭遇开年暴击：明星产品司美格鲁肽仅以4亿美元之差痛失“全球药王”宝座，美国市场突现低价“山寨”司美格鲁肽搅局，口服减肥药被FDA指为虚假宣传，叠加专利悬崖倒计时的大背景，诺和诺德全球防线告急。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602103646576715.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103646576715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVO","NVOH","NVOX","LU1093756325.SGD","BK4532","BK4007","BK4588","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4585","LLY","BK4599","IE00BKVL7J92.USD","LU1093756168.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":17,"pageCount":1,"totalSize":66,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NVOX\",params:#limit:6,delay:false,,,undefined,":[]}}